Literature DB >> 11221130

Predictors of syphilis seroreactivity and prevalence of HIV among street recruited injection drug users in Los Angeles County, 1994-6.

J López-Zetina1, W Ford, M Weber, S Barna, T Woerhle, P Kerndt, E Monterroso.   

Abstract

OBJECTIVES: To describe HIV prevalence and the association between syphilis incidence and sexual and drug injection risk behaviours in a cohort of street recruited injecting drug users (IDUs) in Los Angeles County, between 1994 and 1996.
METHODS: During the study period, 513 street recruited African-American and Latino IDUs were screened for syphilis and antibodies to HIV. Subjects were administered a risk behaviour survey at baseline and followed up at 6 month intervals for 18 months with repeated interviews and serological screening. Rate ratios were used to examine associations between syphilis incidence and demographic characteristics and risk behaviours. A proportional hazard model was used to identify predictors of syphilis incidence independent of demographic characteristics.
RESULTS: 74% of the sample were male, 70% African-American, 30% Latino; and the median age was 43 years. Overall baseline serological prevalence of HIV was 2.5% and of syphilis 5.7%. None of the participants were co-infected for HIV and syphilis at baseline or at any of the 6 month follow ups. Among 390 eligible IDUs retained for analysis of incidence data, the overall syphilis incidence was 26.0 per 1000 person years. Higher syphilis incidence was found for women compared with men (RR = 2.70; 95% CI 1.60, 4.55), and for those 44 years of age or younger compared with those 45 years of age and older (RR = 2.26; 95% CI 1.25, 4.08). African-Americans were more likely to be syphilis incident cases when compared with Latinos, although the difference did not reach statistical significance (RR = 1.27; 95% CI 0.72, 2.23). In bivariate analysis, risk behaviours significantly associated with higher syphilis incidence included injection of cocaine, "speedball" and heroin, "crack" smoking, recency of first injection event, backloading of syringes, injecting with others, exchanging drugs or money for sex, multiple sex partners, and non-heterosexual sexual preference. Variables that significantly predicted syphilis infection at follow up in the multivariate analysis included multiple sex partners (RR = 7.8; 95% CI 2.4, 25.0), exchanging money for sex (RR = 3.0; 95% CI 0.9, 9.6), and recent initiation to injection drug use (RR = 4.6; 95% CI 1.1, 18.8).
CONCLUSION: Syphilis transmission among IDUs in Los Angeles County remains a serious public health concern, particularly among IDUs who engage in trading of sex for money or drugs. Although low, the prevalence of HIV observed in this study constitutes a serious concern because of the potential for expanded HIV transmission in this susceptible population of IDUs with high syphilis incidence. Enhanced case finding screening efforts and prevention of transmission of sexually transmitted infections should specifically target hard to reach IDUs and their sexual partners.

Entities:  

Mesh:

Year:  2000        PMID: 11221130      PMCID: PMC1744247          DOI: 10.1136/sti.76.6.462

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  33 in total

Review 1.  HIV among drug injectors: the epidemic and the response.

Authors:  S R Friedman; D C Des Jarlais
Journal:  AIDS Care       Date:  1991

2.  Cocaine use and HIV infection in intravenous drug users in San Francisco.

Authors:  R E Chaisson; P Bacchetti; D Osmond; B Brodie; M A Sande; A R Moss
Journal:  JAMA       Date:  1989-01-27       Impact factor: 56.272

3.  Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases.

Authors:  T C Quinn; D Glasser; R O Cannon; D L Matuszak; R W Dunning; R L Kline; C H Campbell; E Israel; A S Fauci; E W Hook
Journal:  N Engl J Med       Date:  1988-01-28       Impact factor: 91.245

4.  Sexual risk behavior among heterosexual intravenous drug users: ethnic and gender variations.

Authors:  D K Lewis; J K Watters
Journal:  AIDS       Date:  1991-01       Impact factor: 4.177

5.  Introduction of HIV infection among intravenous drug abusers in low prevalence areas.

Authors:  R J Battjes; R W Pickens; Z Amsel
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

6.  Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up.

Authors:  D S Metzger; G E Woody; A T McLellan; C P O'Brien; P Druley; H Navaline; D DePhilippis; P Stolley; E Abrutyn
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-09

7.  Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco.

Authors:  R E Chaisson; A R Moss; R Onishi; D Osmond; J R Carlson
Journal:  Am J Public Health       Date:  1987-02       Impact factor: 9.308

8.  Sexually transmitted diseases in a population of intravenous drug users: association with seropositivity to the human immunodeficiency virus (HIV).

Authors:  K E Nelson; D Vlahov; S Cohn; M Odunmbaku; A Lindsay; J C Antohony; E W Hook
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

9.  Seroepidemiology of viral infections among intravenous drug users in northern California.

Authors:  J B Zeldis; S Jain; I K Kuramoto; C Richards; K Sazama; S Samuels; P V Holland; N Flynn
Journal:  West J Med       Date:  1992-01

10.  HIV infection and risk behaviors among intravenous drug users in low seroprevalence areas in the Midwest.

Authors:  H A Siegal; R G Carlson; R Falck; L Li; M A Forney; R C Rapp; K Baumgartner; W Myers; M Nelson
Journal:  Am J Public Health       Date:  1991-12       Impact factor: 9.308

View more
  12 in total

Review 1.  Behavior change and health-related interventions for heterosexual risk reduction among drug users.

Authors:  Salaam Semaan; Don C Des Jarlais; Rob Malow
Journal:  Subst Use Misuse       Date:  2006       Impact factor: 2.164

2.  Younger versus older African Americans: patterns and prevalence of recent illicit drug use.

Authors:  Nicole Ennis Whitehead; Rebecca C Trenz; Larry Keen; Jonathan Rose; William W Latimer
Journal:  J Ethn Subst Abuse       Date:  2014       Impact factor: 1.507

3.  Herpes simplex virus 2 and syphilis among young drug users in Baltimore, Maryland.

Authors:  S S Plitt; S G Sherman; S A Strathdee; T E Taha
Journal:  Sex Transm Infect       Date:  2005-06       Impact factor: 3.519

4.  Incident syphilis infection among people who inject drugs in Tijuana, Mexico.

Authors:  Heather A Pines; Melanie L Rusch; Alicia Vera; Gudelia Rangel; Carlos Magis-Rodriguez; Steffanie A Strathdee
Journal:  Int J STD AIDS       Date:  2015-01-22       Impact factor: 1.359

5.  Sexually Transmitted and Blood-borne Infections Among Patients Presenting to a Low-barrier Substance Use Disorder Medication Clinic.

Authors:  Leah Harvey; Jessica L Taylor; Sabrina A Assoumou; Jessica Kehoe; Elissa M Schechter-Perkins; Edward Bernstein; Alexander Y Walley
Journal:  J Addict Med       Date:  2021 Nov-Dec 01       Impact factor: 3.702

Review 6.  The potential role of biomarkers in HIV preventive vaccine trials.

Authors:  Ellen Maclachlan; Kenneth H Mayer; Ruanne Barnabas; Jorge Sanchez; Beryl Koblin; Ann Duerr
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

Review 7.  Syphilis in drug users in low and middle income countries.

Authors:  Lara S Coffin; Ashley Newberry; Holly Hagan; Charles M Cleland; Don C Des Jarlais; David C Perlman
Journal:  Int J Drug Policy       Date:  2009-04-09

Review 8.  Expanding syphilis testing: a scoping review of syphilis testing interventions among key populations.

Authors:  Jason J Ong; Hongyun Fu; M Kumi Smith; Joseph D Tucker
Journal:  Expert Rev Anti Infect Ther       Date:  2018-04-23       Impact factor: 5.091

Review 9.  Syphilis and human immunodeficiency virus co-infection.

Authors:  Allen S Funnyé; Abbasi J Akhtar
Journal:  J Natl Med Assoc       Date:  2003-05       Impact factor: 1.798

10.  Sensitivity and specificity of point-of-care rapid combination syphilis-HIV-HCV tests.

Authors:  Kristen L Hess; Dennis G Fisher; Grace L Reynolds
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.